WHAT IS BCG THERAPY?
İçerik yapay zeka ile optimize edilmiştir
Intravesical BCG Therapy in Bladder Cancer Management
Bacillus Calmette-Guérin (BCG) therapy is a specialized intravesical immunotherapy used to treat patients diagnosed with high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC). Unlike traditional chemotherapy, BCG does not directly kill cancer cells; instead, it stimulates the body's own immune system to recognize and destroy remaining malignant cells. According to the 2026 European Association of Urology (EAU) Guidelines, intravesical BCG stands as a standard bladder-preserving treatment that significantly reduces the risk of recurrence and disease progression.
What is BCG Therapy?
Bacillus Calmette-Guérin (BCG) is a live attenuated bacterium that has been utilized safely for decades as a primary intravesical immunotherapy for bladder cancer. It is important to note that BCG is not administered intravenously. Instead, the solution is placed directly into the bladder through a small urinary catheter to activate a localized immune response after tumor surgery.
How Does BCG Work?
While chemotherapy attacks cells directly, BCG works by stimulating immune cells within the bladder lining. This immune activation triggers a local defense mechanism against bladder cancer, which helps to:
- Reduce the risk of bladder cancer recurrence.
- Decrease the likelihood of progression to muscle-invasive disease.
- Improve long-term bladder preservation outcomes.
Who Should Receive BCG Therapy?
Based on current international clinical protocols, BCG therapy is generally recommended for specific patient groups. The decision is always individualized according to the pathology report, risk classification, and overall clinical assessment. Candidates typically include:
- Patients with High-risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
- Patients with Carcinoma in Situ (CIS).
- Selected patients with intermediate-risk disease.
How is BCG Administered?
BCG is instilled directly into the bladder via a thin urinary catheter. Once administered, the solution remains inside the bladder for a specified period before being naturally emptied during urination. This procedure is usually performed in an outpatient setting and does not typically require hospitalization.
Duration of BCG Treatment
BCG treatment is not a single application but generally consists of two distinct phases. The total duration depends on the patient's individual risk profile and response to the therapy:
- Induction therapy: The initial phase of treatment.
- Maintenance therapy: Follow-up phases when clinically indicated.
Primary Benefits of BCG Therapy
The main objectives of incorporating BCG into a treatment plan are focused on long-term oncological success. The benefits include:
| Benefit Category | Impact on Patient Health |
|---|---|
| Recurrence | Significantly reduces the return of tumors |
| Progression | Lowers the risk of the cancer becoming muscle-invasive |
| Preservation | Maximizes the chance of keeping the natural bladder |
| Outcomes | Enhances long-term survival and oncological results |
The EAU 2026 Key Message for Patients
The 2026 EAU Guidelines emphasize that intravesical BCG is a gold-standard treatment for appropriately selected high-risk NMIBC patients. To ensure maximum effectiveness, patients should adhere to the following:
- Complete the treatment according to the recommended schedule.
- Never miss scheduled follow-up cystoscopic examinations.
- Promptly report any side effects to the urology team.
BCG Therapy with Assoc. Prof. Dr. Serdar Yalçın
Assoc. Prof. Dr. Serdar Yalçın provides intravesical BCG immunotherapy in Bodrum, Türkiye, strictly following the latest EAU Guidelines. Treatment plans are meticulously individualized based on pathology findings, risk classification, and the patient's overall health status.
Patients from Bodrum, Muğla, and across the globe seek consultation for second opinions and personalized bladder cancer management. The practice is characterized by detailed communication, evidence-based decision-making, and close long-term surveillance.
Conclusion
BCG therapy remains one of the most effective bladder-preserving treatments available for high-risk NMIBC. Achieving the best possible long-term outcomes requires appropriate patient selection, strict adherence to the treatment schedule, and guideline-based follow-up.
Frequently Asked Questions
Is BCG chemotherapy? No. BCG is an immunotherapy that stimulates the body's immune system rather than directly killing cancer cells through chemical agents.
Does every bladder cancer patient need BCG? No. BCG is recommended only for selected patients based on their specific risk profile and current international guidelines.
Can BCG completely cure bladder cancer? BCG significantly reduces the risk of recurrence and progression. However, regular follow-up remains an essential and mandatory part of long-term management.
